Abstract: It refers to a new group of solketal monoesters having excellent solubility power in sunscreens, excellent emollient properties, spreadability and ease of preparing stable aqueous formulas, completely non-toxic, without characteristics that generate eye or skin irritation, which allows its use as a solubilizer and emollients in cosmetic formulations for body use, facial sunscreens, makeup removers and a component for use in “roll on” deodorants. The proposed molecule is obtained from palm kernel oil, coconut oil, macauba oil and glycerin as a solubilizer in the form of cocoyl solketal ester, more particularly solketal monoester prepared from oils and/or fatty acids of coconut, babassu, palm kernel.

Abstract: Antibacterial systems with naturally derived ingredients and compositions comprising them are described. The systems have a first ingredient comprising thymol and a second natural ingredient that includes p-anisic acid, aloe, gluconolactone, tetrahydrocurcumin, 4-hydroxyacetophenone or a mixture thereof.

Abstract: The present invention relates to 2-oxoacids modified for use as stabilizers in non-polar applications, such as applications that contain food fats or oils, or fragrance oils.

Abstract: A topical composition useful in the treatment of inflammatory skin diseases, including glycomacropeptide (GMP), panthenol, and a cosmetologically acceptable vehicle.

Abstract: Disclosed herein are compositions and methods for improving pigmentation. Compositions as described herein comprise one or more peptides.

Abstract: The present invention relates to compositions and methods for improving the appearance of the skin. Compositions comprises at least water, glycerin, sodium PCA, erythritol, Carrageenan (Chondrus Crispus extract), xanthan Gum; hydrolyzed collagen, hexapeptide-9 and a physiologically acceptable medium. Methods comprise applying the compositions to the skin to improve the appearance of aging skin, increasing skin moisturization, refining skin pores and decreasing aging skin pigmentation defects.

Abstract: Provided a liquid crystal composition including ceramide, a method of preparing the same, and a cosmetic composition including the same. According to a liquid crystal composition including various types of ceramide of an aspect and a method of preparing the same, the liquid crystal composition not only has high liquid crystal stability that liquid crystal is maintained even after 4 weeks at a high temperature, but also activities of increasing an amount of ceramide, increasing an expression level of aquaporin 3, increasing an amount of filaggrin, increasing an expression level of hyaluronic acid, increasing an expression level of loricrin, increasing an expression level of involucrin, and increasing a thickness of the skin, resulting in effects usefully available for amelioration of the skin conditions.

Abstract: A fluid cosmetic composition with unusual rheologic characteristics has a formulation comprising 0.1 to 50% by weight of at least one fluid branched polymer obtained by simultaneous reaction from components A. B and C, where A is a linear polymer with a molecular weight Mw between 5000 and 50000 Da, provided with reactive functional groups X in a chain at a concentration between 0.1 and 50 mmol/g of polymer. B is a linear polymer with a molecular weight Mw between 10000 and 100000 Da, having terminal reactive functional groups of type Y capable of reacting with the functional group X in an addition or condensation reaction, and C is a molecule or linear oligomer (or a mixture thereof) with a molecular weight between 50 and 1000 Da, having a reactive functional group Y per molecule, capable of reacting with the functional group X in an addition or condensation reaction. The molar ratio of the functional groups of B and A is between 0.01 and 0.

Abstract: The present invention relates to coated particles in which vegetable wax is provided on the surface of starch particles. The coated particles have an average particle diameter d1 of 0.5 to 20 ?m and a maximum particle diameter d2 being less than 30 ?m and less than 4.0 times the average particle diameter d1. The vegetable wax is contained in an amount of 0.5 to 10.0 wt % in the coated particles. Accordingly, particles having excellent feel characteristics and water repellency can be achieved with a natural material having excellent biodegradability. A method for producing coated particles includes: a step of preparing a dispersion that contains 1 to 20 wt % of starch particles; a step of adding vegetable wax to the dispersion and heating and cooling the mixture to precipitate the vegetable wax on the surface of the starch particles; and a step of subjecting this dispersion to solid-liquid separation to obtain coated particles as a solid.

Abstract: The present application discloses a production process of a convenient and quick-adhesive eyelashes in the technical field of daily necessities, and adopts the following technical solution: comprising the following steps: applying a certain amount of glue to front or back of the root of the grafting eyelashes in direction from root to tip of the hair, the glue consists of the following components: mass percentage content: 37.8-48% isooctyl acrylate; 11.9-13% butyl methacrylate; 6-7% n-butyl acrylate; 0.9-1.5% methyl methacrylate; 0.08-0.2% ethylene glycol diacrylate; 31-42% water; 0.3-1% propylene glycol; 0.07-0.13% tert-butyl peroxide; 0.05-0.15% sodium formaldehyde sulfoxylate; 0.05-0.1% sodium alkyl benzene sulfonate; 0.05-0.1% nonylphenol ethoxylate; 0.04-0.1% DCOIT; 0.1-0.2% ammonium persulfate; 0.05-0.15% sodium bicarbonate and 0.

Abstract: The present invention relates to a composition for treating keratin fibers such as the hair, comprising at least one silicone of formula (I), at least one silicone of formula (II) and at least one coloring agent chosen from pigments, direct dyes and mixtures thereof.

Abstract: The present invention is an emulsified composition, including: (A): a titanium-atom-containing silicone resin; (B): one or more oil agents selected from the group consisting of a hydrocarbon oil, an ester oil, and a silicone oil, the oil agent being able to dissolve the component (A) and being liquid at 25° C.; and (C): water, where the emulsified composition contains no surfactant. Accordingly, an object of the present invention is to provide: an emulsified composition having excellent stability and usability without a surfactant; and a cosmetic material including the above emulsified composition and having excellent feeling of use.

Abstract: A hair treatment grease configured to be applied to a scalp, is disclosed. The hair treatment grease includes at least one oil base comprising at least one part of one or more of tea tree oil, jojoba oil, myrrh oil, frankincense oil, and/or peppermint oil. The hair treatment grease includes at least one fat-soluble antioxidant formed into a mixture with the at least one oil base.

Abstract: Provided is a method of improving skin condition by applying to the skin of a subject a cosmetic composition comprising black yeast-derived exosomes as an active ingredient and thereby improving the skin condition, particularly skin elasticity improvement, skin wrinkle reduction, skin texture improvement, skin tone improvement, skin brightness improvement, skin regeneration, skin moisturization, and/or whitening.

Abstract: The product is made of phytotherapeutic active substances extracted from roots, stems and leaves of medicinal plants, biological emulsifier, synthetic active substances of organic origin in small quantities, minerals and water. The product is made in the oil, water and dry phases according to best manufacturing practice to obtain a high-quality cream to treat acne and melasma safely, quickly and effectively. The cream can be used to treat all skin types, is applied to the affected area, and has anti-inflammatory, antiseptic, antioxidant, healing, anti-fungicidal, moisturizing and skin-lightening properties.

Abstract: A tooth paste composition comprising black cumin oil (Nigella sativa) and fluoride-doped bioactive glass, zinc oxide, and/or titanium oxide is disclosed.

Abstract: A nature-based cleansing composition includes at least one glycolipid that includes at least one rhamnolipid, at least one nature-based viscosity modifying polymeric thickener for a water-based system or at least one anionic surfactant, or a combination thereof, and water present from about 60% to about 98% by weight of the cleansing composition. The at least one nature-based viscosity modifying polymeric thickener for a water-based system may be one of algin, xanthan gum (and) sclerotium gum (and) lecithin (and) pullulan (Siligel™), xanthan gum, carbomer 980, hydroxypropyl starch phosphate, ammonium polyacryloyldimethyl taurate, hydroxyethyl cellulose, acrylate copolymer, sclerotium gum.

Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Abstract: Provided are systems and miniature devices configured to navigate within a patient to a location therewithin for delivering to induce a localized therapeutic effect. Specifically, the present disclosure provides miniature devices configured to be remotely maneuvered along a path within the patient, where the miniature device is configured to selectively: (i) release a guide substance; (ii) release a payload that induces a physiological response; and/or (iii) produce a microtrauma at locations along the path. Further provided are various methods of treatment using such systems and devices.

Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

Abstract: The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior to the application of lenses or other matrix on the eye surface. After such matrix is positioned on the eye, MTC is translocated from the lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.

Abstract: The present disclosure generally relates to a soft chewable formulation, especially suitable for delivering active ingredients to animals and processes for preparation thereof. In some embodiments of the disclosure, a soft chewable veterinary formulation includes a starch, one or more carbohydrates, a flavoring agent, a lipid, and at least one active ingredients. In accordance with some embodiments, the starch in the soft chewable formulations includes a certain ratios of regular starch and pre-gelatinized starch.

Abstract: Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

Abstract: Stable composition of anhydrous micronized ipratropium or a pharmaceutically acceptable anhydrous salt thereof and method of making.

Abstract: Disclosed is a process for the manufacture of the self-nanoemulsifying drug delivery systems (SNEDDS) of the present invention by a process that comprises: (a) combining (i) a therapeutic amount of one or more tryptamine-scaffold psychedelics, (ii) a triglyceride oil, (iii) a first surfactant, (iv) a second surfactant, and, optionally, (v) an anti-oxidant in a container, (b) adding a lower chain alcohol to said container while mixing the ingredients therein to form a pre-emulsion product, (c) optionally cooling said pre-emulsion product, and (d) diluting the pre-emulsion product with water to form a self-nanoemulsifying drug delivery system.

Abstract: This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1,1,1,2-tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoropropane.

Abstract: Disclosed herein are compositions that include nicotinamide adenine dinucleotide (NAD), precursors thereof, derivatives thereof, or mixtures thereof encapsulated in a liposome, wherein the compositions exhibit enhanced chemical, physical, and/or microbial storage stability at a variety of storage temperatures. In certain embodiments, the compositions are stable and have positive permeability and senescence results. Also disclosed herein are methods for preparing such compositions and methods of using such compositions.

Abstract: The present invention provides: a liquid-crystal polyester solution composition which changes little in solution viscosity with the flow initiation temperature of the liquid-crystal polyester powder, and a liquid-crystal polyester powder useful for the liquid-crystal polyester solution composition. This liquid-crystal polyester powder is soluble in aprotic solvents and is characterized in that the proportion of particles having a particle diameter, as determined by dry sieving test according to JIS K 0069 (1992), of less than 250 ?m is 23.5 mass % or less. The present invention further provides a method for producing the liquid-crystal polyester solution composition, the method comprising dissolving the liquid-crystal polyester powder in an aprotic solvent to obtain the liquid-crystal polyester solution composition.

Abstract: Methods and formulations for a simplified, single-injection method to induce and control the synchronous growth (superstimulation), and ovulation (superovulation) of multiple ovarian follicles in bovine, ovine, caprine, camelid and other female animals enabling the subsequent collection of (a) multiple oocytes when conducting in-vitro fertilization, or (b) multiple embryos when conducting multiple ovulation embryo transfer.

Abstract: This disclosure relates to macro- and micro-sized elastin-like polymers (ELP). The addition of a polyethyleneimine (PEI) block to the terminal end of ELP allows the particle radius as well as LCST to be controlled by changing any combination of polymer concentration, ion concentration, and pH. The addition of the PEI block also provides the ability to crosslink the copolymers and achieve a stable particle radius.

Abstract: The present disclosure belongs to the technical field of medicines, and specifically, relates to a core-shell micelle microsphere, and a preparation method therefor and use thereof. The core-shell micelle microsphere of the present disclosure has an outer layer shell composed of an amphiphilic lipid, an inner layer shell formed by a hydrophilic chain polymer, and a drug molecule inner core wrapped by a copolymer with a net structure. A drug may be effectively transported through the two-layer shell structure, such that a loss of the drug in a transportation process is reduced, and a utilization rate of the drug is improved. A slow release of the drug is realized by using a wrapped drug molecule as the inner core.

Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.

Abstract: The present Invention relates to a pellet comprising melatonin and methods of treating insomnia.

Abstract: The invention relates to a method for preparing co-processed excipient granules using a co-rotating twin-screw extruder, wherein at least one binder and at least one superdisintegrant are granulated together, and wherein the binder and the superdisintegrant are introduced into the extruder in different points. The invention also relates to co-processed excipient granules obtained or obtainable by the method. The invention further relates to the use of the co-processed excipient granules in a tableting process.

Abstract: Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable human papilloma virus (HPV) formulation or other stabilized multimeric virus formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lyophilizing HPV capsomere vaccines in order to increase stability of an immunogenic composition against HPV infection for storage, delivery and use. In yet other embodiments, a single immunogenic composition can include a thermally stable formulation of multiple virus serotypes. Yet other embodiments disclosed herein concern multi-targeted antigen complexes lyophilized in formulations of use to prolong stability and/or enhance immunogenicity. Other embodiments concern exposing lyophilized multi-targeted antigen complexes to elevated temperatures to enhance immunogenicity of the antigens of the complex to multiple pathogens.

Abstract: The instant invention relates to a printable material for Hot Melt Extrusion-based 3D printing (HME-3DP) comprising a pregelatinized cross-linked starch and hydroxypropyl methyl cellulose (HPMC). It also relates to a process for 3D printing using the same. It also relates to products, in particular controlled release solid dosage forms, obtained thereof by 3D printing.

Abstract: The present invention relates to an erodible tablet comprising a therapeutic peptide which is suitable for oral administration and, in addition, to a non-granulation process for making the erodible tablet.

Abstract: The present invention relates to the field of coating pharmaceutical substrates. In particular, the invention relates to methods of coating of pharmaceutical substances, pharmaceutical ingredients or a blend of them. The invention also provides a method of making a pharmaceutical formulation which may be processed into a pharmaceutical dosage form, which utilizes solid pharmaceutical particles and a pharmaceutical formulation obtained by the method. The methods of the invention utilize atomic layer deposition technology. The novel methods allow difficult, moisture sensitive and electrically charged pharmaceutical substrates to be easily processable.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The disclosure provides formulations comprising sotorasib (1), a diluent, a disintegrant and a lubricant.

Abstract: A drug delivery device includes a foam body having a negative Poisson's ratio, the foam body formed of a material configured to dissolve in a biological fluid; and a liquid drug contained in cells of the foam body, the drug exerting a pressure on walls of the cells that is above atmospheric pressure.

Abstract: A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: The invention relates to a composition of orlistat and acarbose for use in improving quality of life. The combination is administered orally to obtain a synergistic effect. The synergistic effect is obtained after 13 weeks or more such a after 14 weeks or more. after 15 weeks or more. after 16 weeks or more. after 17 weeks or more. after 18 weeks or more. after 19 weeks or more. after 20 weeks or more. after 21 weeks or more. after 22 weeks or more. after 23 weeks or more. after 24 weeks or more. after 25 weeks or more of after 26 weeks or more of treatment. The synergistic effect gives improved weight loss.

Abstract: This disclosure relates to messenger RNA (mRNA) therapy for the treatment of methylmalonic acidemia. mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase. mRNA therapies of the disclosure increase and/or restore deficient levels of MUT expression and/or activity in subjects.

Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

Abstract: This invention discloses an injectable nanocomposite gel composition and the method of making the composition. The composition is composed of amphiphilic alginate nanoparticle, gel stabilizer, gel crosslinker, and gel structural modifiers. The nanocomposite gel can be manufactured into a form of highly-viscous gel or a solid-like gel, used as a vehicle to carry and deliver pharmaceutically active ingredients with high drug load via injection administration for medical uses.

Abstract: Aspects of the present disclosure relate to methods of preparing lyophilized compositions comprising lipid, nanoparticles and nucleic acids. Other aspects relate to lyophilized compositions with low moisture contents and improved stability during long-term storage.

Abstract: Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.

Abstract: An aspect is a composition containing at least one of inositol, erythritol or sorbitol and formulated for administration to a subject such that the at least one of inositol, erythritol or sorbitol enhance growth of Faecalibacterium prausnitzii in the microbiome of the subject. Another aspect is a method to treat, prevent, reduce a severity of, and/or reduce an incidence of a pathological condition in the subject, and the method includes enhancing growth of Faecalibacterium prausnitzii in the microbiome of the subject by administering, to the subject, at least one of inositol, erythritol or sorbitol. Yet another aspect is a method to achieve at least one of a metabolic effect, an anti-aging effect, or an anti-inflammatory effect in a subject, and the method includes enhancing growth of Faecalibacterium prausnitzii in the microbiome of the subject by administering, to the subject, at least one of inositol, erythritol or sorbitol.